Tenax Therapeutics shares are trading higher after the company announced it received a Notice of Allowance from the USPTO for its patent application covering the use of TNX-103 in pulmonary hypertension with heart failure with preserved ejection fraction.
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics received a Notice of Allowance from the USPTO for its patent application covering the use of TNX-103 in pulmonary hypertension with heart failure with preserved ejection fraction. This has led to an increase in the company's share price.
May 31, 2023 | 5:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenax Therapeutics' shares are trading higher after receiving a Notice of Allowance from the USPTO for its TNX-103 patent application.
The Notice of Allowance from the USPTO for Tenax Therapeutics' patent application covering the use of TNX-103 is a positive development for the company. This news directly impacts the company's intellectual property portfolio and future revenue potential, leading to an increase in the share price. As a result, the short-term impact on the stock price is likely to be positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100